Abiraterone acetate

Red

Brand Name(s):Zytiga

Indication:Prostate Cancer – metastatic castration resistant in patients whose disease has progressed on or after a docetaxel-based chemotherapy regimen. Intended for use in combination with prednisone.
Metastatic hormone-relapsed prostate cancer before chemotherapy is indicated

Rationale:1,2,8

Considered:Sep-11

Review Date:Aug-26

Comments:
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer
Technology appraisal guidance [TA721]Published: 18 August 2021 …………………………Update of TA 259 Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen
Updated July 2016
…………………………